$7.77
+3.02 (+63.58%)
Open$6.01
Previous Close$4.75
Day High$8.07
Day Low$5.99
52W High$7.12
52W Low$3.22
Volume—
Avg Volume140.8K
Market Cap146.19M
P/E Ratio—
EPS$-1.57
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+345.4% upside
Current
$7.77
$7.77
Target
$34.61
$34.61
$23.82
$34.61 avg
$34.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 78.77M | 61.71M | 25.19M |
| Net Income | -53,446,429 | -37,679,606 | -2,467,246 |
| Profit Margin | -67.9% | -64.5% | -9.8% |
| EBITDA | -44,206,164 | -32,896,644 | -4,050,890 |
| Free Cash Flow | — | — | -1,532,934 |
| Rev Growth | +27.7% | +27.7% | +20.8% |
| Debt/Equity | 9.39 | 9.39 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |